Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Jiangsu Alphamab","sponsor":"Glenmark Pharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines Announce the Signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"CHINA","productType":"Large molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Jiangsu Alphamab

    Menu

    Jiangsu Alphamab

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Jiangsu Alphamab

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag China
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Glenmark, Jiangsu Alphamab Biopharmaceuticals and 3D Medicines Announce the Signing of a License Agreement for KN035 (Envafolimab) for Multiple Geographies around the World

              Details:

              Glenmark will be responsible for further developing, registering, and commercializing KN035 (envafolimab), approved in China for the treatment of adult patients with previously treated MSI-H or dMMR advanced solid tumor, in multiple geographies around the World.

              Lead Product(s): Envafolimab

              Therapeutic Area: Oncology Product Name: KN035

              Highest Development Status: Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Glenmark Pharmaceuticals

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement January 25, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY